Chakraborty R - Search Results

1

Impact of bone marrow minimal residual disease status on quality of organ response in systemic AL amyloidosis.

Chakraborty R, Hopson M, Bhutani D, Vlad G, Maurer MS, Griffin JM, Mapara MY, Radhakrishnan J, Lentzsch S. Chakraborty R, et al. Am J Hematol. 2022 Jul;97(7):E244-E246. doi: 10.1002/ajh.26562. Epub 2022 Apr 14. Am J Hematol. 2022. PMID: 35385144 Free article. No abstract available.

2

Emerging drugs for the treatment of light chain amyloidosis.

Chakraborty R, Lentzsch S. Chakraborty R, et al. Expert Opin Emerg Drugs. 2020 Sep;25(3):299-317. doi: 10.1080/14728214.2020.1803829. Epub 2020 Aug 24. Expert Opin Emerg Drugs. 2020. PMID: 32731778 Review.

3

Prognostic impact of t(11;14) in multiple myeloma: Black and white or shades of gray?

Chakraborty R, Lentzsch S. Chakraborty R, et al. Cancer. 2021 Jan 1;127(1):31-34. doi: 10.1002/cncr.33206. Epub 2020 Sep 23. Cancer. 2021. PMID: 32966668 Free article. No abstract available.

4

Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis.

Bhutani D, Pan S, Latif F, Goldsmith RL, Saith SE, Mapara MY, Chakraborty R, Lentzsch S, Maurer MS. Bhutani D, et al. Among authors: chakraborty r. Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):545-548. doi: 10.1016/j.clml.2021.03.015. Epub 2021 Apr 23. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34024744

5

Impact of light chain isotype on clinical features and outcomes in systemic AL amyloidosis.

Hopson MB, Bhutani D, Sarkaria S, Maurer MS, Griffin JM, Mapara M, Lentzsch S, Chakraborty R. Hopson MB, et al. Among authors: chakraborty r. Leuk Lymphoma. 2022 Sep;63(9):2109-2113. doi: 10.1080/10428194.2022.2060502. Epub 2022 Apr 23. Leuk Lymphoma. 2022. PMID: 35465769

6

How do we manage t(11;14) plasma cell disorders with venetoclax?

Chakraborty R, Bhutani D, Lentzsch S. Chakraborty R, et al. Br J Haematol. 2022 Oct;199(1):31-39. doi: 10.1111/bjh.18243. Epub 2022 May 20. Br J Haematol. 2022. PMID: 35594184 Review.

7

Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?

Chakraborty R, Lentzsch S. Chakraborty R, et al. J Clin Oncol. 2022 Sep 20;40(27):3099-3102. doi: 10.1200/JCO.22.01040. Epub 2022 Jun 27. J Clin Oncol. 2022. PMID: 35759726 No abstract available.

8

Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects.

Li S, Fu J, Walker CJ, Yang J, Bhutani D, Chakraborty R, Mamillapalli N, Mapara MY, Landesman Y, Lentzsch S. Li S, et al. Among authors: chakraborty r. Blood Adv. 2023 Jun 27;7(12):2926-2937. doi: 10.1182/bloodadvances.2021006638. Blood Adv. 2023. PMID: 36827679 Free PMC article.

9

First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.

Chakraborty R, Rosenbaum C, Kaur G, Bhutani D, Radhakrishnan J, Mapara MY, Maurer M, Lentzsch S. Chakraborty R, et al. Br J Haematol. 2023 Jun;201(5):913-916. doi: 10.1111/bjh.18733. Epub 2023 Mar 10. Br J Haematol. 2023. PMID: 36896578

10

How do we image patients with multiple myeloma and precursor states?

Chakraborty R, Hillengass J, Lentzsch S. Chakraborty R, et al. Br J Haematol. 2023 Nov;203(4):536-545. doi: 10.1111/bjh.18880. Epub 2023 May 22. Br J Haematol. 2023. PMID: 37217164

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,549 results

Search Page

Filters